Member Info for doze

BoJo did defer to science and scientists in top positions at Oxford mainly and got the vaccine rolling. The political clout and science which should have received as urgent an emphasis for LFTs was absent; they have their hads round it now but too late to save lives. Omicron is unlikely to push sales for AffiDX in the retail space unless mandated but should be ordered for healthcare settings.
Hopefully no tests available is heralding something and anything will be welcome and support good therapeutic, AVA6000 news.

They have morphed into socialist/communist interference at the same time as being in thrall to big pharma. A schizoid approach.

Lecture delivered 23/11/21 https://www.youtube.com/watch?v=tG_a0P2qybE

Virus like peptide vaccines subjected to non pandemic procurement processes so a north od England company lost out. Very similar to how AVCT have lost out. Emergency use for our LFT was needed and deserved just like the Oxford–AstraZeneca COVID-19 vaccine AZD1222. 31 min to 37 min is the relevant bit for my comment but like the cut of her jib generally

A subsidiary in the EU would be a good idea.

Why was spreadbet margin news glorious for him. I thought he was a shareholder. My spreadbet is just for fun but his might be serious and would colour his twitter feed. No capital gains tax for spreadbet profits and a young man might be attracted to this more risky strategy.

Just checked that it does indeed say unborrowable under special info which I regard as strange and don't understand why they don't provide for both directions.

If you have a long open you need to use the force open option otherwise close all longs and then sell.

Sounds very good tech; they use a human cell instead of an affimer to bind though I imagine the sample could not be subjected to a buffer to make the virus inert if it has to do its thing. Any improved variant must bind better to the human cell so no need to rejig the binder/human cell. It has been around a while;21/12/20 ; " its technology works as a trapdoor using COVID-19 virus’ own mechanism of cell entry to generate signal. All the other antigen tests work by identifying the nucleocapsid protein in the centre of the virus, which is not a real measure of infectivity. " https://www.uktech.news/news/covid-19-20201221

There is no point to that apart from wasting time and money. The best we can hope for is positive evaluation from Europe and having that springboard to produce a pregnancy test and all the other markets to aim for.

We know the N protein tests are ineffective at stopping spread so whether ours works or not it should be on the market. How will the powers that be defend themselves when eventually it is proved our test could have saved lives?

Our test works when the virus is active and affimers bind in the region of the spikes not with the spikes. The N protein on its own is not infectious as it is spikes that attach to a host target and the N protein is not necessarily present in an active infection whereas the S protein when on the envelope of the active virus is the infectious virus stage which the AffiDX® SARS-CoV-2 Antigen Lateral Flow Test is designed to detect.
Virus Genomic Structure
The current COVID-19 pandemic is caused by the novel coronavirus strain SARS-CoV-2, a positive-sense, single-stranded enveloped RNA belonging to the Coronaviridae family12 (Figure 1A). The SARS-CoV-2 genome is >30 kb in length and consists of 14 open reading frames (ORFs) encoding 27 proteins.13 The 5' end of the SARS-CoV-2 genome consists of ORF1a/b encoding a polyprotein that is post-translationally cleaved into 16 non-structural proteins (nsp1–16), which form the replicase/transcriptase complex (RTC). This complex contains enzymes involved in the replication mechanism, including papain-like protease (nsp3), main protease (nsp5), nsp7-nsp8 primase complex, primary RNA-dependent RNA polymerase (RdRp; nsp12), helicase/triphosphatase (nsp13), exoribonuclease (nsp14), endonuclease (nsp15), and N7- and 2'-O-methyltransferases (nsp10/nsp16). The 3' terminus of the viral genome contains ORFs encoding the four main structural proteins, spike (S), envelope (E), membrane (M), and nucleocapsid (N), as well as nine putative accessory factors (Figure 1B).14,15https://www.dovepress.com/cr_data/article_fulltext/s306000/306441/img/IDR_A_306441_O_F0001g.jpg

Validation batches sent to PD will not be relevant for EU notified body who maybe accept different route.

I think Medusa have been doing the field test for a year already and assume that is the evidence for HUA.

They all use Ehrlich, a shoe in for the EU list https://www.pei.de/DE/newsroom/dossier/coronavirus/coronavirus-inhalt.html;jsessionid=04E55676A371143BF675C2E00C632EE0.intranet232?nn=169730&cms_pos=8

If AffiDX® SARS-CoV-2 Antigen Lateral Flow Test could be validated in US that is another route. It is only a test, will not hurt anyone and should just be allowed to sell if it does the job. Would have saved lots of lives. The regulators have allowed vaccines because they do the job because the bigwig scientists OKed them and bigpharma saw the gravy train. Our test would not hit their bottom line but stoke a rival potential world pharma biotech company.

All are nucleocapsid, an independant validation study needs to bypass Paul-Ehrlich-Institut (https://ec.europa.eu/health/sites/default/files/preparedness_response/docs/covid-19_rat_common-list_en.pdf ) and not use Roche( https://diagnostics.roche.com/global/en/products/systems/cobas_-8100-automated-workflow-series.html ) which may disadvantage the spike protein. It is a great opportunity for a rival validation service to claim the space in Europe with a better test to Ehrlich validated ones.

the notified bodies that is!

they are sat on our affimer though

https://en.wikipedia.org/wiki/Wind_power_in_Japan
Increase wind power and excess can go to green hydrogen instead of blue via CWR to fuel all those fuel cells.